Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Urinary Bladder Neoplasms"" wg kryterium: Temat


Tytuł:
Mesenchymal neoplasms of the urinary bladder: a comprehensive review with focus on cross-sectional imaging findings.
Autorzy:
Balasubramanya R; Department of Radiology, Thomas Jefferson University Hospital, Philadelphia, USA.
Shanbhogue AK; New York University School of Medicine, New York, USA.
Ramani NS; Department of Pathology, Michael E DeBakey VA Medical Center, Houston, USA.
Morani AC; Department of Abdominal Imaging, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1473, Houston, TX, 77030, USA.
Khandelwal A; Mayo Clinic, Rochester, USA.
Prasad SR; Department of Abdominal Imaging, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1473, Houston, TX, 77030, USA. .
Pokaż więcej
Źródło:
Abdominal radiology (New York) [Abdom Radiol (NY)] 2022 Aug; Vol. 47 (8), pp. 2881-2895. Date of Electronic Publication: 2022 Jun 15.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Urinary Bladder*/pathology
Urinary Bladder Neoplasms*/diagnostic imaging
Urinary Bladder Neoplasms*/pathology
Diagnostic Imaging ; Humans ; Pelvis/pathology
Czasopismo naukowe
Tytuł:
Mortality prediction models after radical cystectomy for bladder tumour: A systematic review and critical appraisal.
Autorzy:
Sarrió-Sanz P; Urology Services, University Hospital of San Juan de Alicante, Alicante, Spain.
Martinez-Cayuelas L; Urology Services, University Hospital of San Juan de Alicante, Alicante, Spain.
Lumbreras B; Department of Public Health, History of Science and Gynecology, Miguel Hernández University, and CIBER en Epidemiología y Salud Pública, Alicante, Spain.
Sánchez-Caballero L; Urology Services, University Hospital of San Juan de Alicante, Alicante, Spain.
Palazón-Bru A; Department of Clinical Medicine, Miguel Hernández University, Alicante, Spain.
Gil-Guillén VF; Department of Clinical Medicine, Miguel Hernández University, Alicante, Spain.
Gómez-Pérez L; Department of Clinical Medicine, Miguel Hernández University, Alicante, Spain.; Urology Services, University General Hospital of Elx, Alicante, Spain.
Pokaż więcej
Źródło:
European journal of clinical investigation [Eur J Clin Invest] 2022 Oct; Vol. 52 (10), pp. e13822. Date of Electronic Publication: 2022 Jun 13.
Typ publikacji:
Journal Article; Review; Systematic Review
MeSH Terms:
Cystectomy*
Urinary Bladder Neoplasms*/pathology
Urinary Bladder Neoplasms*/surgery
Humans ; Prospective Studies ; Systematic Reviews as Topic ; Treatment Outcome ; Urinary Bladder/pathology ; Urinary Bladder/surgery
Czasopismo naukowe
Tytuł:
Impact of preoperative chemotherapy on pathologic nodal status in muscle-invasive bladder cancer: optimal lymphadenectomy in the preoperative chemotherapy era.
Autorzy:
Lee W; Department of Urology, Hallym University Dongtan Sacred Heart Hospital, Hwaseong, Korea.
Nam W; Department of Urology, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, Korea.
Lim B; Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, 388-1 Pungnap2-dong, Songpa-gu, Seoul, 138-736, Korea.
Kyung YS; Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, 388-1 Pungnap2-dong, Songpa-gu, Seoul, 138-736, Korea.
Kim CS; Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, 388-1 Pungnap2-dong, Songpa-gu, Seoul, 138-736, Korea.
Ahn H; Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, 388-1 Pungnap2-dong, Songpa-gu, Seoul, 138-736, Korea.
Hong B; Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, 388-1 Pungnap2-dong, Songpa-gu, Seoul, 138-736, Korea. .
Pokaż więcej
Źródło:
Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 2022 Sep; Vol. 148 (9), pp. 2507-2515. Date of Electronic Publication: 2021 Sep 23.
Typ publikacji:
Journal Article
MeSH Terms:
Urinary Bladder Neoplasms*/drug therapy
Urinary Bladder Neoplasms*/surgery
Cystectomy/methods ; Humans ; Lymph Node Excision ; Lymph Nodes/pathology ; Lymph Nodes/surgery ; Lymphatic Metastasis/pathology ; Muscles/pathology ; Neoplasm Staging ; Retrospective Studies
Czasopismo naukowe
Tytuł:
Systematic Review of the Incidence of and Risk Factors for Urothelial Cancers and Renal Cell Carcinoma Among Patients with Haematuria.
Autorzy:
Rai BP; Department of Urology, Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK. Electronic address: .
Luis Dominguez Escrig J; Department of Urology, Fundación Instituto Valenciano de Oncología, Valencia, Spain.
Vale L; Department of Urology, Centro Hospital Universitário S. João, Porto, University of Porto, Porto, Portugal.
Kuusk T; Department of Urology, Darent Valley Hospital, Dartford and Gravesham NHS Trust, Dartford, UK.
Capoun O; Department of Urology, General University Hospital, First Faculty of Medicine, Charles University, Prague, Czech Republic.
Soukup V; Department of Urology, General University Hospital, First Faculty of Medicine, Charles University, Prague, Czech Republic.
Bruins HM; Department of Urology, Zuyderland Medical Center, Sittard-Geleen-Heerlen, The Netherlands.
Yuan Y; Department of Medicine, Health Science Centre, McMaster University, Hamilton, ON, Canada.
Violette PD; Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada; Department of Surgery, Division of Urology, McMaster University, Hamilton, ON, Canada.
Santesso N; Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada; Michael G. DeGroote Cochrane Canada Centre, McMaster University, Hamilton, ON, Canada.
van Rhijn BWG; Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
Hugh Mostafid A; Department of Urology, Royal Surrey County Hospital, Guildford, UK.
Imran Omar M; Academic Urology Unit, University of Aberdeen, Aberdeen, UK.
Pokaż więcej
Źródło:
European urology [Eur Urol] 2022 Aug; Vol. 82 (2), pp. 182-192. Date of Electronic Publication: 2022 Apr 05.
Typ publikacji:
Journal Article; Review; Systematic Review
MeSH Terms:
Carcinoma, Renal Cell*/complications
Carcinoma, Renal Cell*/epidemiology
Carcinoma, Transitional Cell*/complications
Carcinoma, Transitional Cell*/epidemiology
Kidney Neoplasms*/complications
Kidney Neoplasms*/epidemiology
Urinary Bladder Neoplasms*/complications
Urinary Bladder Neoplasms*/epidemiology
Cross-Sectional Studies ; Hematuria/epidemiology ; Hematuria/etiology ; Humans ; Incidence ; Male ; Prospective Studies ; Retrospective Studies ; Risk Factors
Czasopismo naukowe
Tytuł:
The impact of low-pressure pneumoperitoneum on robotic-assisted radical cystectomy and intracorporeal ileal conduit urinary diversion: a case-control study.
Autorzy:
Kostakopoulos N; Department of Urology, Aberdeen Royal Infirmary, NHS Grampian, Aberdeen, Scotland, UK.; Academic Urology Unit, University of Aberdeen, Aberdeen, Scotland, UK.
Athanasiadis G; Department of Urology, Aberdeen Royal Infirmary, NHS Grampian, Aberdeen, Scotland, UK.; Academic Urology Unit, University of Aberdeen, Aberdeen, Scotland, UK.
Omar MI; Academic Urology Unit, University of Aberdeen, Aberdeen, Scotland, UK.
Abraham J; Department of Urology, Aberdeen Royal Infirmary, NHS Grampian, Aberdeen, Scotland, UK.
Dimitropoulos K; Department of Urology, Aberdeen Royal Infirmary, NHS Grampian, Aberdeen, Scotland, UK. .; Academic Urology Unit, University of Aberdeen, Aberdeen, Scotland, UK. .
Pokaż więcej
Źródło:
World journal of urology [World J Urol] 2022 Oct; Vol. 40 (10), pp. 2467-2472. Date of Electronic Publication: 2022 Sep 05.
Typ publikacji:
Journal Article
MeSH Terms:
Ileus*/epidemiology
Ileus*/etiology
Pneumoperitoneum*/complications
Pneumoperitoneum*/surgery
Robotic Surgical Procedures*/methods
Urinary Bladder Neoplasms*/complications
Urinary Bladder Neoplasms*/surgery
Urinary Diversion*/methods
Case-Control Studies ; Cystectomy/methods ; Humans ; Margins of Excision ; Operative Time ; Pain ; Postoperative Complications/etiology ; Retrospective Studies ; Treatment Outcome
Czasopismo naukowe
Tytuł:
Checklist for Improving Patient Communication on Bladder Preservation Options: The Patient Advocate Perspective.
Autorzy:
Bangs R; Bladder Cancer Advocacy Network, Bethesda, Maryland, USA. Electronic address: .
Quale DZ; Bladder Cancer Advocacy Network, Bethesda, Maryland, USA.
Reed T; Bladder Cancer Advocacy Network, Bethesda, Maryland, USA.
Pokaż więcej
Źródło:
Clinical oncology (Royal College of Radiologists (Great Britain)) [Clin Oncol (R Coll Radiol)] 2022 Oct; Vol. 34 (10), pp. 625-629. Date of Electronic Publication: 2022 Sep 01.
Typ publikacji:
Journal Article
MeSH Terms:
Cystectomy*
Urinary Bladder Neoplasms*/pathology
Urinary Bladder Neoplasms*/surgery
Checklist ; Combined Modality Therapy ; Communication ; Humans ; Neoplasm Invasiveness/pathology ; Patient Advocacy ; Urinary Bladder
Czasopismo naukowe
Tytuł:
p53 gene delivery via a recombinant Salmonella enterica Typhimurium leads to human bladder carcinoma cell death in vitro.
Autorzy:
Pérez Jorge G; Department of Genetics, Evolution, Microbiology, and Immunology, Tropical Disease Laboratory, Institute of Biology, University of Campinas - UNICAMP, Campinas, SP, Brazil.
Módolo DG; Genetics Laboratory, Butantan Institute, São Paulo, SP, Brazil.
Jaimes-Florez YP; Department of Genetics, Evolution, Microbiology, and Immunology, Tropical Disease Laboratory, Institute of Biology, University of Campinas - UNICAMP, Campinas, SP, Brazil.
Fávaro WJ; Department of Structural and Functional Biology, Institute of Biology, University of Campinas - UNICAMP, Campinas, SP, Brazil.
de Jesus MB; Department of Biochemistry and Tissue Biology, Institute of Biology, University of Campinas - UNICAMP, Campinas, SP, Brazil.
Brocchi M; Department of Genetics, Evolution, Microbiology, and Immunology, Tropical Disease Laboratory, Institute of Biology, University of Campinas - UNICAMP, Campinas, SP, Brazil.
Pokaż więcej
Źródło:
Letters in applied microbiology [Lett Appl Microbiol] 2022 Oct; Vol. 75 (4), pp. 1010-1020. Date of Electronic Publication: 2022 Jul 02.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma*/genetics
Urinary Bladder Neoplasms*/genetics
Urinary Bladder Neoplasms*/therapy
Cell Death ; Genes, p53 ; Humans ; Salmonella typhimurium/genetics ; Tumor Suppressor Protein p53/genetics ; Tumor Suppressor Protein p53/metabolism ; Urinary Bladder
Czasopismo naukowe
Tytuł:
Bempegaldesleukin plus Nivolumab in First-line Metastatic Urothelial Carcinoma: Results from PIVOT-02.
Autorzy:
Siefker-Radtke AO; University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: .
Cho DC; New York Medical College, Westchester Medical Center, Valhalla, NY, USA.
Diab A; University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sznol M; Yale Cancer Center, New Haven, CT, USA.
Bilen MA; Winship Cancer Institute of Emory University, Atlanta, GA, USA.
Balar AV; New York Medical College, Westchester Medical Center, Valhalla, NY, USA.
Grignani G; Division of Medical Oncology, Candiolo Cancer Institute FPO-IRCCS, Candiolo, Turin, Italy.
Puente E; Nektar Therapeutics, San Francisco, CA, USA.
Tang L; Nektar Therapeutics, San Francisco, CA, USA.
Chien D; Nektar Therapeutics, San Francisco, CA, USA.
Hoch U; Nektar Therapeutics, San Francisco, CA, USA.
Choudhury A; Nektar Therapeutics, San Francisco, CA, USA.
Yu D; Nektar Therapeutics, San Francisco, CA, USA.
Currie SL; Nektar Therapeutics, San Francisco, CA, USA.
Tagliaferri MA; Nektar Therapeutics, San Francisco, CA, USA.
Zalevsky J; Nektar Therapeutics, San Francisco, CA, USA.
Hurwitz ME; Yale Cancer Center, New Haven, CT, USA.
Tannir NM; University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Pokaż więcej
Źródło:
European urology [Eur Urol] 2022 Oct; Vol. 82 (4), pp. 365-373. Date of Electronic Publication: 2022 May 25.
Typ publikacji:
Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study
MeSH Terms:
Carcinoma, Transitional Cell*/drug therapy
Carcinoma, Transitional Cell*/secondary
Prodrugs*/therapeutic use
Urinary Bladder Neoplasms*/drug therapy
Urinary Bladder Neoplasms*/etiology
Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Humans ; Interleukin-2/therapeutic use ; Nivolumab/adverse effects
Czasopismo naukowe
Tytuł:
Clinicopathological Features of FGFR3 - Mutated Upper Tract Urothelial Carcinoma: A Genomic Database Analysis.
Autorzy:
Rizzo A; Struttura Semplice Dipartimentale di Oncologia Medica per la Presa in Carico Globale del Paziente Oncologico 'Don Tonino Bello,' I.R.C.C.S. Istituto Tumori 'Giovanni Paolo II,' Bari, Italy. Electronic address: .
Mollica V; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Santoni M; Oncology Unit, Macerata Hospital, Macerata, Italy.
Massari F; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.
Pokaż więcej
Źródło:
Clinical genitourinary cancer [Clin Genitourin Cancer] 2022 Oct; Vol. 20 (5), pp. 482-487. Date of Electronic Publication: 2022 Jun 18.
Typ publikacji:
Journal Article
MeSH Terms:
Biological Products*
Carcinoma, Transitional Cell*/pathology
Ureter*/surgery
Urinary Bladder Neoplasms*/genetics
Urinary Bladder Neoplasms*/pathology
Genomics ; Humans ; Receptor, Fibroblast Growth Factor, Type 3/genetics
Czasopismo naukowe
Tytuł:
Clinical evidence and insights supporting the use of avelumab first-line maintenance treatment in patients with advanced urothelial carcinoma in the Asia-Pacific region.
Autorzy:
Eto M; Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Lee JL; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Chang YH; Taipei Veterans General Hospital, Taipei, Taiwan.
Gao S; Merck Pte. Ltd., Singapore, an affiliate of Merck KGaA.
Singh M; Pfizer Corporation Hong Kong Ltd., Hong Kong.
Gurney H; Department of Clinical Medicine, Macquarie University, Sydney, New South Wales, Australia.
Pokaż więcej
Źródło:
Asia-Pacific journal of clinical oncology [Asia Pac J Clin Oncol] 2022 Oct; Vol. 18 (5), pp. e191-e203. Date of Electronic Publication: 2022 Mar 03.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Antibodies, Monoclonal, Humanized*/adverse effects
Carcinoma, Transitional Cell*/drug therapy
Carcinoma, Transitional Cell*/pathology
Urinary Bladder Neoplasms*/drug therapy
Urinary Bladder Neoplasms*/pathology
Cisplatin/therapeutic use ; Clinical Trials, Phase III as Topic ; Humans ; Immune Checkpoint Inhibitors/therapeutic use
Czasopismo naukowe
Tytuł:
The increasing indications of FDG-PET/CT in the staging and management of Invasive Bladder Cancer.
Autorzy:
Omorphos NP; Department of Urology, Heartlands Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK. Electronic address: .
Ghose A; Department of Medical Oncology, Barts Cancer Centre, St. Bartholomew's Hospital, London, Barts Health NHS Trust, UK; Faculty of Life Sciences and Medicine, King's College London, London, UK; Department of Medical Oncology, Mount Vernon Cancer Centre, East and North Hertfordshire NHS Trust, London, UK.
Hayes JDB; Department of Urology, Lister Hospital, East and North Hertfordshire NHS Trust, Stevenage, UK; School of Life and Medical Sciences, University of Hertfordshire, Northwood, UK.
Kandala A; Department of Urology, Lister Hospital, East and North Hertfordshire NHS Trust, Stevenage, UK.
Dasgupta P; Faculty of Life Sciences and Medicine, King's College London, London, UK; Department of Urology, Guy's Hospital, Guy's and St. Thomas' NHS Foundation Trust, London, UK; Apollo Hospitals Educational and Research Foundation (AHERF), Chennai, India.
Sharma A; School of Life and Medical Sciences, University of Hertfordshire, Northwood, UK; Department of Medical Oncology, Mount Vernon Cancer Centre, East and North Hertfordshire NHS Trust, London, UK; Brunel University, London, UK.
Vasdev N; Department of Urology, Lister Hospital, East and North Hertfordshire NHS Trust, Stevenage, UK; School of Life and Medical Sciences, University of Hertfordshire, Northwood, UK; Apollo Hospitals Educational and Research Foundation (AHERF), Chennai, India.
Pokaż więcej
Źródło:
Urologic oncology [Urol Oncol] 2022 Oct; Vol. 40 (10), pp. 434-441. Date of Electronic Publication: 2022 Jul 06.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Fluorodeoxyglucose F18*/therapeutic use
Urinary Bladder Neoplasms*/drug therapy
Urinary Bladder Neoplasms*/therapy
Humans ; Lymph Nodes/pathology ; Lymphatic Metastasis/pathology ; Neoplasm Staging ; Positron Emission Tomography Computed Tomography/methods ; Positron-Emission Tomography/methods ; Radiopharmaceuticals/therapeutic use ; Sensitivity and Specificity ; Tomography, X-Ray Computed
Czasopismo naukowe
Tytuł:
Practice trends for perioperative intravesical chemotherapy in upper tract urothelial carcinoma: Low but increasing utilization during minimally invasive nephroureterectomy.
Autorzy:
Kenigsberg AP; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX.
Carpinito G; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX.
Gold SA; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX.
Meng X; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX.
Ghoreifi A; Institute of Urology & Catherine and Joseph Aresty Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA.
Djaladat H; Institute of Urology & Catherine and Joseph Aresty Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA.
Minervini A; Unit of Oncologic Minimally-Invasive Urology and Andrology, Department of Experimental and Clinical Medicine, University of Florence, Careggi Hospital, Florence, Italy.
Jamil M; Vattikuti Urology Institute, Henry Ford Hospital, Detroit, MI.
Abdollah F; Vattikuti Urology Institute, Henry Ford Hospital, Detroit, MI.
Farrow JM; Department of Urology, Indiana University School of Medicine, Indianapolis, IN.
Sundaram C; Department of Urology, Indiana University School of Medicine, Indianapolis, IN.
Uzzo R; Division of Urologic Oncology, Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.
Ferro M; Division of Urology, IRCCS European Institute of Oncology, Milan, Italy.
Meagher M; Department of Urology, UCSD School of Medicine, La Jolla, CA.
Derweesh I; Department of Urology, UCSD School of Medicine, La Jolla, CA.
Wu Z; Department of Urology, Changzheng Hospital, Second Military (Naval) Medical University, Shanghai, China.
Porter J; Swedish Urology Group, Seattle, WA.
Katims A; Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY.
Mehrazin R; Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY.
Mottrie A; Department of Urology, Onze Lieve Vrouw Hospital, Aalst, Belgium.
Simone G; Department of Urology, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Reese AC; Department of Urology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA.
Eun DD; Department of Urology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA.
Bhattu AS; Desai Sethi Urology Institute, University of Miami Miller School of Medicine, Miami, FL.
Gonzalgo ML; Desai Sethi Urology Institute, University of Miami Miller School of Medicine, Miami, FL.
Carbonara U; Division of Urology and Massey Cancer Center, VCU Health System, Richmond, VA.
Autorino R; Division of Urology and Massey Cancer Center, VCU Health System, Richmond, VA.
Margulis V; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX. Electronic address: .
Pokaż więcej
Źródło:
Urologic oncology [Urol Oncol] 2022 Oct; Vol. 40 (10), pp. 452.e17-452.e23. Date of Electronic Publication: 2022 Aug 04.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Transitional Cell*/drug therapy
Carcinoma, Transitional Cell*/surgery
Ureteral Neoplasms*/drug therapy
Ureteral Neoplasms*/surgery
Urinary Bladder Neoplasms*/drug therapy
Urinary Bladder Neoplasms*/surgery
Administration, Intravesical ; Humans ; Neoplasm Recurrence, Local/surgery ; Nephroureterectomy/methods ; Retrospective Studies
Czasopismo naukowe
Tytuł:
Mivebresib synergized with PZ703b, a novel Bcl-xl PROTAC degrader, induces apoptosis in bladder cancer cells via the mitochondrial pathway.
Autorzy:
Xu Y; Department of Urology, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou, Zhejiang, 324000, PR China; Department of Urology, Quzhou People's Hospital, Quzhou, Zhejiang, 324000, PR China. Electronic address: .
Lei Z; Department of Urology, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou, Zhejiang, 324000, PR China; Department of Urology, Quzhou People's Hospital, Quzhou, Zhejiang, 324000, PR China.
Zhu J; Department of Urology, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou, Zhejiang, 324000, PR China; Department of Urology, Quzhou People's Hospital, Quzhou, Zhejiang, 324000, PR China.
Wan L; Department of Urology, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou, Zhejiang, 324000, PR China; Department of Urology, Quzhou People's Hospital, Quzhou, Zhejiang, 324000, PR China. Electronic address: wanlijun_.
Pokaż więcej
Źródło:
Biochemical and biophysical research communications [Biochem Biophys Res Commun] 2022 Oct 01; Vol. 623, pp. 120-126. Date of Electronic Publication: 2022 Jul 16.
Typ publikacji:
Journal Article
MeSH Terms:
Urinary Bladder Neoplasms*/drug therapy
Urinary Bladder Neoplasms*/genetics
Apoptosis ; Apoptosis Regulatory Proteins/genetics ; Apoptosis Regulatory Proteins/metabolism ; Cell Line, Tumor ; Humans ; Intercellular Signaling Peptides and Proteins ; Myeloid Cell Leukemia Sequence 1 Protein/metabolism ; Proto-Oncogene Proteins c-bcl-2/genetics ; Proto-Oncogene Proteins c-bcl-2/metabolism ; Pyridones ; Sulfonamides ; bcl-X Protein/genetics ; bcl-X Protein/metabolism
Czasopismo naukowe
Tytuł:
An exceptionally rare case of metastatic high-grade urothelial carcinoma of the renal pelvis to the pancreas diagnosed on endoscopic ultrasound-guided fine-needle aspiration: A diagnostic challenge.
Autorzy:
Koyuncuer A; Department of Pathology, Umraniye Training and Research Hospital, University of Health Sciences, Istanbul, Turkey.
Sayar S; Department of Gastroenterology, Health Sciences University, Umraniye Training and Research Hospital, İstanbul, Turkey.
Zemheri IE; Department of Pathology, Umraniye Training and Research Hospital, University of Health Sciences, Istanbul, Turkey.
Özdil K; Department of Gastroenterology, Health Sciences University, Umraniye Training and Research Hospital, İstanbul, Turkey.
Özçelik M; Department of Medical Oncology, Health Sciences University, Umraniye Training and Research Hospital, İstanbul, Turkey.
Pokaż więcej
Źródło:
Diagnostic cytopathology [Diagn Cytopathol] 2022 Oct; Vol. 50 (10), pp. E295-E300. Date of Electronic Publication: 2022 Jun 02.
Typ publikacji:
Case Reports; Journal Article
MeSH Terms:
Carcinoma, Transitional Cell*/diagnosis
Carcinoma, Transitional Cell*/pathology
Pancreatic Neoplasms*/pathology
Urinary Bladder Neoplasms*/diagnosis
Urinary Bladder Neoplasms*/pathology
Aged ; Endoscopic Ultrasound-Guided Fine Needle Aspiration/methods ; Humans ; Kidney Pelvis/pathology ; Male ; Pancreas/pathology
Czasopismo naukowe
Tytuł:
Cytologic features of micropapillary variant urothelial carcinoma in urinary tract cytology: Case series and review of literature.
Autorzy:
Greenland NY; Department of Anatomic Pathology, University of California, San Francisco, CA, USA.; Department of Anatomic Pathology, San Francisco Veterans Affairs Health Care System, San Francisco, CA, USA.
Peng Y; Department of Anatomic Pathology, University of California, San Francisco, CA, USA.; Department of Anatomic Pathology, San Francisco Veterans Affairs Health Care System, San Francisco, CA, USA.
Vohra P; Department of Anatomic Pathology, University of California, San Francisco, CA, USA.; Department of Anatomic Pathology, Zuckerberg San Francisco General, San Francisco, CA, USA.
Tabatabai ZL; Department of Anatomic Pathology, University of California, San Francisco, CA, USA.; Department of Anatomic Pathology, San Francisco Veterans Affairs Health Care System, San Francisco, CA, USA.
Pokaż więcej
Źródło:
Diagnostic cytopathology [Diagn Cytopathol] 2022 Oct; Vol. 50 (10), pp. E280-E284. Date of Electronic Publication: 2022 May 20.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Carcinoma, Papillary*/pathology
Carcinoma, Transitional Cell*/diagnosis
Carcinoma, Transitional Cell*/pathology
Urinary Bladder Neoplasms*/diagnosis
Urinary Bladder Neoplasms*/pathology
Urinary Tract*/pathology
Humans ; Reproducibility of Results ; Urothelium/pathology
Czasopismo naukowe
Tytuł:
Pioglitazone use in Australia and the United Kingdom following drug safety advisories on bladder cancer risk: An interrupted time series study.
Autorzy:
Kemp-Casey A; School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia.
Mintzes B; Charles Perkins Centre and School of Pharmacy, The University of Sydney, Sydney, Australia.
Morrow RL; Department of Anesthesiology, Pharmacology & Therapeutics, University of British Columbia, Victoria, Canada.
Dormuth CR; Department of Anesthesiology, Pharmacology & Therapeutics, University of British Columbia, Victoria, Canada.
Souverein PC; Division of Pharmacoepidemiology and Clinical Pharmacology, Universiteit Utrecht, Utrecht, The Netherlands.
Roughead EE; School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia.
Pokaż więcej
Źródło:
Pharmacoepidemiology and drug safety [Pharmacoepidemiol Drug Saf] 2022 Oct; Vol. 31 (10), pp. 1039-1045. Date of Electronic Publication: 2022 Jul 27.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Diabetes Mellitus, Type 2*
Thiazolidinediones*/adverse effects
Urinary Bladder Neoplasms*/chemically induced
Urinary Bladder Neoplasms*/epidemiology
Aged ; Australia/epidemiology ; Female ; Humans ; Hypoglycemic Agents/adverse effects ; Interrupted Time Series Analysis ; Male ; Pioglitazone/adverse effects ; United Kingdom/epidemiology
Czasopismo naukowe
Tytuł:
Mapping Local Failure Following Bladder Radiotherapy According to Dose.
Autorzy:
Abdel-Aty H; Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK; Department of Radiotherapy, The Royal Marsden NHS Foundation Trust, London, UK.
Warren-Oseni K; Joint Department of Physics, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK.
Bagherzadeh-Akbari S; Joint Department of Physics, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK.
Hansen VN; Department of Oncology, Section of Radiotherapy, Rigshospitalet, Copenhagen, Denmark.
Jones K; Department of Radiotherapy, The Royal Marsden NHS Foundation Trust, London, UK.
Harris V; Department of Radiotherapy, Guy's & St. Thomas' NHS Foundation Trust, London, UK.
Tan MP; Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK; Department of Radiotherapy, The Royal Marsden NHS Foundation Trust, London, UK.
Mcquaid D; Joint Department of Physics, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK.
McNair HA; Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK; Department of Radiotherapy, The Royal Marsden NHS Foundation Trust, London, UK.
Huddart R; Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK; Department of Radiotherapy, The Royal Marsden NHS Foundation Trust, London, UK.
Dunlop A; Joint Department of Physics, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK.
Hafeez S; Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK; Department of Radiotherapy, The Royal Marsden NHS Foundation Trust, London, UK. Electronic address: .
Pokaż więcej
Źródło:
Clinical oncology (Royal College of Radiologists (Great Britain)) [Clin Oncol (R Coll Radiol)] 2022 Oct; Vol. 34 (10), pp. e421-e429. Date of Electronic Publication: 2022 Jun 09.
Typ publikacji:
Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Radiotherapy, Intensity-Modulated*/adverse effects
Radiotherapy, Intensity-Modulated*/methods
Urinary Bladder Neoplasms*/diagnostic imaging
Urinary Bladder Neoplasms*/radiotherapy
Cross-Sectional Studies ; Humans ; Neoplasm Recurrence, Local/diagnostic imaging ; Neoplasm Recurrence, Local/pathology ; Neoplasm Recurrence, Local/radiotherapy ; Radiotherapy Dosage ; Radiotherapy Planning, Computer-Assisted/methods ; Urinary Bladder/diagnostic imaging
Czasopismo naukowe
Tytuł:
Re: Ekaterina Laukhtina, Shahrokh F. Shariat. Phase II Study of Gemcitabine and Split-dose Cisplatin plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients with Muscle-invasive Bladder Cancer. Eur Urol. 2022;82:242-3.
Autorzy:
Takahashi T; Health and Welfare Bureau, Kitakyushu City Office, Kitakyushu, Japan. Electronic address: .
Pokaż więcej
Źródło:
European urology [Eur Urol] 2022 Oct; Vol. 82 (4), pp. e107-e108. Date of Electronic Publication: 2022 Jul 02.
Typ publikacji:
Clinical Trial, Phase II; Letter
MeSH Terms:
Cystectomy*
Urinary Bladder Neoplasms*/drug therapy
Urinary Bladder Neoplasms*/surgery
Antibodies, Monoclonal, Humanized ; Cisplatin ; Deoxycytidine/analogs & derivatives ; Humans ; Muscles ; Neoadjuvant Therapy
Raport
Tytuł:
Downregulation of BLM RecQ helicase inhibits proliferation, promotes the apoptosis and enhances the sensitivity of bladder cancer cells to cisplatin.
Autorzy:
Feng S; Department of Urology, Beijing Chao‑Yang Hospital, Capital Medical University, Beijing 100020, P.R. China.
Qian X; Department of Urology, Beijing Chao‑Yang Hospital, Capital Medical University, Beijing 100020, P.R. China.
Feng D; Department of Urology, Beijing Chao‑Yang Hospital, Capital Medical University, Beijing 100020, P.R. China.
Zhang X; Department of Urology, Beijing Chao‑Yang Hospital, Capital Medical University, Beijing 100020, P.R. China.
Pokaż więcej
Źródło:
Molecular medicine reports [Mol Med Rep] 2022 Oct; Vol. 26 (4). Date of Electronic Publication: 2022 Aug 25.
Typ publikacji:
Journal Article
MeSH Terms:
Cisplatin*/pharmacology
RecQ Helicases*/genetics
Urinary Bladder Neoplasms*/drug therapy
Urinary Bladder Neoplasms*/genetics
Apoptosis/genetics ; Cell Proliferation/genetics ; Down-Regulation ; Humans ; Urinary Bladder/metabolism
Czasopismo naukowe
Tytuł:
Urodynamic assessment and quality of life outcomes of robot-assisted totally intracorporeal radical cystectomy and orthotopic neobladder for bladder cancer: a preliminary study.
Autorzy:
Grobet-Jeandin E; Division of Urology, Geneva University Hospitals, Geneva, Switzerland.; Department of Urology, Sorbonne Université, GRC n°5, Predictive Onco-urology, Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Paris, France.
Benamran D; Division of Urology, Geneva University Hospitals, Geneva, Switzerland.; Department of Urology, Sorbonne Université, GRC n°5, Predictive Onco-urology, Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Paris, France.
Pinar U; Department of Urology, Sorbonne Université, GRC n°5, Predictive Onco-urology, Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Paris, France.
Beirnaert J; Department of Urology, Sorbonne Université, GRC n°5, Predictive Onco-urology, Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Paris, France.; Service d'Urologie, Hôpital Erasme, Cliniques Universitaires de Bruxelles, Brussels, Belgium.
Parra J; Department of Urology, Sorbonne Université, GRC n°5, Predictive Onco-urology, Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Paris, France.
Vaessen C; Department of Urology, Sorbonne Université, GRC n°5, Predictive Onco-urology, Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Paris, France.
Seisen T; Department of Urology, Sorbonne Université, GRC n°5, Predictive Onco-urology, Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Paris, France.
Rouprêt M; Department of Urology, Sorbonne Université, GRC n°5, Predictive Onco-urology, Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Paris, France.
Phé V; Department of Urology, Sorbonne Université, GRC n°5, Predictive Oncology, Assistance Publique-Hôpitaux de Paris, AP-HP Sorbonne Université, Tenon Hospital, 4 rue de la Chine, 75020, Paris, France. .
Pokaż więcej
Źródło:
World journal of urology [World J Urol] 2022 Oct; Vol. 40 (10), pp. 2535-2541. Date of Electronic Publication: 2022 Aug 22.
Typ publikacji:
Journal Article; Observational Study
MeSH Terms:
Erectile Dysfunction*/etiology
Robotic Surgical Procedures*/methods
Robotics*
Urinary Bladder Neoplasms*/etiology
Urinary Bladder Neoplasms*/surgery
Urinary Diversion*/methods
Urinary Incontinence*/epidemiology
Urinary Incontinence*/etiology
Urinary Incontinence*/surgery
Cystectomy/methods ; Humans ; Male ; Middle Aged ; Quality of Life ; Treatment Outcome ; Urodynamics
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies

Prześlij opinię

Twoje opinie są dla nas bardzo ważne i mogą być niezwykle pomocne w pokazaniu nam, gdzie możemy dokonać ulepszeń. Bylibyśmy bardzo wdzięczni za poświęcenie kilku chwil na wypełnienie krótkiego formularza.

Formularz